Lydase (Hyaluronidase) lyophilisate for solution preparation 1280 IU
21928USD

Lydase (Hyaluronidase) lyophilisate for solution preparation 1280 IU

SKU:2267
To favorites
Lydase (Hyaluronidase) Lydase (Hyaluronidase) an enzyme preparation isolated from the testicles of cattle reduces tissue swelling, softens and flattens scars, increases the range of motion in the joints, reduces contractures and prevents their formation
Active substance:Hyaluronidase
Pharmacological group:Dermatology
Formulation:ampoules
Dosage mg:64
In stock
In stock
$19
11
Description
Features
Reviews

Instructions for Lydase (Hyaluronidase) lyophilisate for solution preparation

English product name
Lydase-M

Release Form Hyaluronidase
lyophilizate d/r-fit d/injection and local approx. 1280 IU: amp. 5, 10, 20, 25, 50, 60, 100, 120, 200 units, fl. 5 or 10 pcs, with or without solvent

Description Lydase

Lyophilizate for injection preparation and local application 1 fl
hyaluronidase

ATC codes Hyaluronidase
B06AA03 Hyaluronidase

Clinical-pharmacological groups / Group affiliation Lydase
Preparation having proteolytic activity

Active substance
hyaluronidase

Pharmaco-therapeutic group Lydase

Enzyme agent

Pharmacological effect Hyaluronidase

A seed-derived enzyme from the seeds of cattle. Cleaves the main component of the interspecific substance of the connective tissue - hyaluronic acid (mucopolysaccharide, which includes acetylglucosamine and glucuronic acid, is a cementing substance of the connective tissue). Hyaluronidase causes hyaluronic acid to decay to glucosamine and glucuric acid and thus reduces its viscosity. The invention makes it possible to increase tissue and vascular permeability and to ease the diffusion of liquids in the intertissue space. Reduces swelling of the tissue, softens and flattens the scars, increases the volume of movements in the joints, reduces contracture and prevents their formation.
In parenteral administration (n/c and v/m), a single dose is 1280 IU.
Hyaluronidase has a reversible effect: when the concentration of hyaluronic acid decreases, the viscosity of the hyaluronic acid is restored.
In parenteral administration (n/c and v/m), a single dose is 1280 IU.
Duration of action in / for the introduction - up to 48 hours.
In parenteral administration (n/c and v/m), a single dose is 1280 IU.
Testimony
Burn, traumatic, post-surgery scars; long-term non-healing ulcers (including radiation); Dupuytren contracture; stiff joints mobility, joint contracture (after inflammatory processes, injuries), osteoarthrosis, ankylosing spondyloarthritis, severe diseases of the lumbar discs; chronic tendovaginitis, scleroderma (skin manifestations), soft tissue hematoma surface localization; preparation for skin-plastic operations on scar contractions.
In parenteral administration (n/c and v/m), a single dose is 64 UE.

Method of use, course and dosage Lydase

In parenteral administration (n/c and v/m), a single dose is 1280 IU.
For inhalation, retrobulbar administration and for application to the conjunctiva, the dose is set individually, depending on the indications.

Special Instructions Hyaluronidase

The solution should not be injected through a catheter into which solutions containing cations were previously introduced.
Before starting treatment, it is advisable to carry out a test with b/c introduction of hyaluronidase.
Do not inject into the areas of infectious inflammation and tumour.

  • Nosology Hyaluronidase (ICD codes)
  • A15
  • Respiratory tuberculosis confirmed bacteriologically and histologically
  • G54
  • Lesions of the nerve spine and plexus
  • H17
  • Scarring and clouding of the cornea
  • H35.0
  • Background retinopathy and retinal vascular changes
  • H36.0
  • Diabetic retinopathy
  • H43.1
  • Vitreous hemorrhage
  • L90.5
  • Scarring and skin fibrosis
  • L91
  • Hypertrophic changes of the skin
  • L98.4
  • Chronic skin ulcer not classified in other categories
  • M15
  • Polyarthrosis
  • M24.5
  • Joint contracture
  • M25.6
  • Joint stiffness not classified in other headings
  • M34
  • Systemic sclerosis
  • M45
  • Ankylosing spondylitis
  • M47
  • Spondylosis
  • M51.9
  • Intervertebral disc lesion unspecified
  • M65
  • Synovitis and tenosinovites
  • M72.0
  • Brass fascial fibromatosis [Dupuytren]
  • M79.2
  • Neuralgia and Neuritis Unspecified
  • T14.0
  • Superficial injury of an unspecified area of the body (including abrasion, bruising, bruising, hematoma, bite of a non-venomous insect)
  • Z51.4
  • Preparatory procedures for follow-up treatment or examination not classified elsewhere
Features
Active substance
Pharmacological group
Formulation
Dosage mg
Country of origin
Brand
Expiration Date
No reviews yet — your comment may be first.
All reviews 0
general rating
Also buying with this item
Proserin (neostigmine methylsulphate)
SKU:1689
$14
In stock